Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 13,615 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Cancer
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2015
U.S. locations: 1
States / cities: Duarte, California

Conditions: Atopic Dermatitis
Interventions: Dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 40
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2/Neu-positive Breast Cancer
Interventions: Capecitabine, Lapatinib; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Hamilton, New Jersey • New Brunswick, New Jersey

Conditions: Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions: SNP analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Relapsed Breast Cancer, Neoplasms, Breast
Interventions: Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more

Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions: BYL719, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Lafayette, Indiana

Conditions: Acne Vulgaris
Interventions: CTGel/ BPO Wash, Soap Free Cleanser and CTGel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 5
States / cities: Coral Gables, Florida • Warren, Michigan • High Point, North Carolina + 2 more

Conditions: Breast Carcinoma, Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Prostate Carcinoma, Tobacco Use
Interventions: Communication Skills Training, Medical Chart Review, Questionnaire Administration, Tobacco Cessation Counseling; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: HER-2 pulsed Dendritic Cell Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Locally Recurrent and Metastatic Breast Cancer
Interventions: AMG 386 Placebo, AMG 386, Bevacizumab, Paclitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer
Interventions: Leflunomide; Drug
Lead sponsor: Joseph Sparano; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: temozolomide, thalidomide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 132
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Castro Valley, California + 89 more

Conditions: Rosacea
Interventions: Metronidazole gel 1%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
Interventions: ONC201; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions: Mepolizumab, Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 14
States / cities: Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more

Conditions: Psoriasis
Interventions: placebo, CT 327; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Breast Cancer
Interventions: surveys completed by subject; Other
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Skin Rash
Interventions: Acitretin; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Carcinoma
Interventions: Enhanced Consultation, Standard of Care Consultation, Conventional Imaging, Educational Intervention, Questionnaire Administration; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acne Vulgaris
Interventions: Visonac PDT, Vehicle cream with PDT; Drug
Lead sponsor: Photocure; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more

Conditions: Scleroderma, Systemic
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more

Conditions: Plaque-type Psoriasis
Interventions: CD 2027; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Hot Springs, Arizona • Austin, Texas • Bryan, Texas

Conditions: BRCA1 Mutation, BRCA2 Mutation
Interventions: Web + Streamlined Telephone Genetic Information; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania

Search by objective public record fields.

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

Predictive Genetic Risk Assessment Trial

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

CT 327 in the Treatment of Psoriasis Vulgaris

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Genetic Education in BRCA Families